Light-initiated chemiluminescence immunoassay (LiCA), as a novel chemiluminescence immunoassay, has been gradually recognized and successfully applied in the clinical laboratories to some extent.
Different from electrochemiluminescence, direct chemiluminescence and enzymatic chemiluminescence, LiCA has a very unique signaling mechanism. The basic principle of LiCA technology can be described as: when the sensitizer beads are within the proximity of emission beads (within 200 nm distance) through high affinity interactions (including antibody/antigen, protein/protein, or protein/small molecular interactions), the sensitizer beads then can effectively deliver singlet oxygen molecules to the emission beads after laser excitation, which triggers a cascade of chemical reactions inside the emission beads to initiate a chemiluminescent event. The chemiluminescent event results in emission of certain wavelength of light to be detected by the LiCA instrument.
Based on the LiCA platform, dozens of clinical immunoassays have been developed, including markers for infectious diseases, tumor markers, thyroid hormones, fertility hormones and cardiac markers.
LiCA systems are favorited in clinical laboratories because of the characteristics of easy operation, high throughput and very low required maintenance.
Light-initiated chemiluminescence immunoassay (LiCA), as a novel chemiluminescence immunoassay, has been gradually recognized and successfully applied in the clinical laboratories to some extent.
Different from electrochemiluminescence, direct chemiluminescence and enzymatic chemiluminescence, LiCA has a very unique signaling mechanism. The basic principle of LiCA technology can be described as: when the sensitizer beads are within the proximity of emission beads (within 200 nm distance) through high affinity interactions (including antibody/antigen, protein/protein, or protein/small molecular interactions), the sensitizer beads then can effectively deliver singlet oxygen molecules to the emission beads after laser excitation, which triggers a cascade of chemical reactions inside the emission beads to initiate a chemiluminescent event. The chemiluminescent event results in emission of certain wavelength of light to be detected by the LiCA instrument.
Based on the LiCA platform, dozens of clinical immunoassays have been developed, including markers for infectious diseases, tumor markers, thyroid hormones, fertility hormones and cardiac markers.
LiCA systems are favorited in clinical laboratories because of the characteristics of easy operation, high throughput and very low required maintenance.
Light-initiated chemiluminescence immunoassay (LiCA), as a novel chemiluminescence immunoassay, has been gradually recognized and successfully applied in the clinical laboratories to some extent.
Different from electrochemiluminescence, direct chemiluminescence and enzymatic chemiluminescence, LiCA has a very unique signaling mechanism. The basic principle of LiCA technology can be described as: when the sensitizer beads are within the proximity of emission beads (within 200 nm distance) through high affinity interactions (including antibody/antigen, protein/protein, or protein/small molecular interactions), the sensitizer beads then can effectively deliver singlet oxygen molecules to the emission beads after laser excitation, which triggers a cascade of chemical reactions inside the emission beads to initiate a chemiluminescent event. The chemiluminescent event results in emission of certain wavelength of light to be detected by the LiCA instrument.
Based on the LiCA platform, dozens of clinical immunoassays have been developed, including markers for infectious diseases, tumor markers, thyroid hormones, fertility hormones and cardiac markers.
LiCA systems are favorited in clinical laboratories because of the characteristics of easy operation, high throughput and very low required maintenance.
NANOSCALE
HOMOGENEOUS
LIGHT-INITIATED
